Standard BioTools Inc (LAB): Next-Year EPS Estimate 25.64%

As of 2026-05-11, Standard BioTools Inc (LAB) has a next-year EPS growth estimate of 25.64%.

Analyst estimates for LAB have remained steady in the most recent observable window, with next-year EPS growth projected at 25.64%. Current-year growth stands at 13.33%.

Current Snapshot

Sector
Healthcare
Industry
Medical Devices
EPS growth next year
25.64%
EPS growth this year
13.33%
EPS next quarter (est)
-$0.02
Last price
$0.99

EPS Revision History

26.6%24.6%05-0605-11
Next-year EPS growth estimate · 4 observations
40.0%38.0%05-0605-11
Combined EPS growth (this year + next year) · 4 observations
DateEPS Next YEPS This YNext Q (est)Price
2026-05-1125.64%13.33%-$0.02$0.99
2026-05-1025.64%13.33%-$0.02$1.02
2026-05-0725.64%13.33%-$0.02$1.00
2026-05-0625.64%13.33%-$0.02$0.97

Recent News

Screen Performance

Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.

Median return since detection
+5.1%
% of tickers in the green
62%
Median return on winners
+17.5%
Large revisions captured
746

Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.

Frequently Asked Questions

What is Standard BioTools Inc's next-year EPS growth estimate?

As of 2026-05-11, Standard BioTools Inc (LAB) has a next-year EPS growth estimate of 25.64%, based on analyst consensus.

What sector and industry does Standard BioTools Inc belong to?

Standard BioTools Inc operates in the Healthcare sector, specifically the Medical Devices industry.

How often is this EPS estimate data updated?

EPS revision data is refreshed daily from analyst consensus estimates. LAB appears on this page because it was flagged by our daily top-EPS-revision-performer screen.

EPS revision data sourced from analyst consensus estimates, refreshed daily. Standard BioTools Inc (LAB) appears here because it was detected by our daily top-EPS-revision-performer screen.

← All reports